PLD-IN-1
Product Specifications
UNSPSC Description
PLD-IN-1 (Compound 3r) is an orally active inhibitor for phospholipase D with an IC50 of 1.97 μM. PLD-IN-1 reduces the expression of CD24, CD47 and PD-L1, enhances the calreticulin expression, and thus modulates the immune evasion mechanism in lung cancer cells by promoting the phagocytosis of cancer cells by macrophages. PLD-IN-1 inhibits the cell viability of lung cancer cell A549, HCC44, H460 and HCC15 with IC50 of 18.44, 22.31, 24.85 and 21.45 μM, respectively. PLD-IN-1 can induce apoptosis and inhibits migration in cell A549. PLD-IN-1 enhances the level of pro-inflammatory M1 macrophages and decreases the level of anti-inflammatory M2 macrophages, exhibits antitumor efficacy in mouse model[1].
Target Antigen
Apoptosis; Phospholipase
Type
Reference compound
Related Pathways
Apoptosis;Metabolic Enzyme/Protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pld-in-1.html
Smiles
O=C(NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)CCC2=CNC3=C2C=CC=C3
Molecular Weight
400.32
References & Citations
[1]Song D, et al., Development and Evaluation of Indole-Based Phospholipase D Inhibitors for Lung Cancer Immunotherapy. J Med Chem. 2024 Oct 15.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-169262/PLD-IN-1-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-169262/
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items